<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57108">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362620</url>
  </required_header>
  <id_info>
    <org_study_id>CNI-DOC-2014-02</org_study_id>
    <secondary_id>CNIO-CP-02-2014</secondary_id>
    <nct_id>NCT02362620</nct_id>
  </id_info>
  <brief_title>PROSTAC: Prospective Multi-centre Study of Prognostic Factors in CRPC Treated With Docetaxel or Cabazitaxel</brief_title>
  <acronym>PROSTAC</acronym>
  <official_title>Prospective Multi-centre Study of Prognostic Factors in Castration Resistant PROState Cancer Treated With doceTaxel or Cabazitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Nacional de Investigaciones Oncologicas CARLOS III</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Nacional de Investigaciones Oncologicas CARLOS III</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Multi-centre Study of Prognostic Factors in Castration Resistant PROState Cancer
      Treated With doceTaxel and Cabazitaxel (PROSTAC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational study to analyze prognostic factors in castration resistant prostate cancer
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prognostic value for global survival</measure>
    <time_frame>months</time_frame>
    <description>Independently validate the prognostic value for global survival of the expression signature in peripheral blood of nine genes characterised by Olmos et al. (Lancet Oncol., 2012) in two cohorts of patients with castration-resistant prostate cancer (CRPC) who are candidates for treatment with Taxotere o cabazitaxel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>months</time_frame>
    <description>Analyse (in an independent and joint manner in the two cohorts) the prognostic value for the progression-free survival (PSA and radiological) of the expression signature described by Olmos et al. (Lancet Oncol., 2012).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global survival of the early changes</measure>
    <time_frame>months</time_frame>
    <description>Study the prognostic value for global survival of the early changes (prior to receiving the third cycle of treatment) in expression signatures described by Olmos et al. (Lancet Oncol., 2012) in an independent and joint manner in the two cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic value for global survival</measure>
    <time_frame>months</time_frame>
    <description>Evaluate the prognostic value for global survival (PSA and radiological) of the early changes in expression signatures described by Olmos et al. (Lancet Oncol., 2012) in an independent and joint manner in the two cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical response to the treatment</measure>
    <time_frame>months</time_frame>
    <description>Study the asociation or not of the for biochemical response to the treatment with the expression signature described by Olmos et al. (Lancet Oncol., 2012) in an independent and joint manner in the two cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic and predictive utility</measure>
    <time_frame>months</time_frame>
    <description>Compare the prognostic and predictive utility of the expression signature described by Olmos et al. (Lancet Oncol., 2012) with that described by Ross et al., (Lancet Oncol., 2012) in an independent and joint manner in the two cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic nomograms described for CRPC</measure>
    <time_frame>months</time_frame>
    <description>Validate in these two patient cohorts treated with docetaxel or cabazitaxel, the prognostic nomograms described for CRPC in terms of the clinical, pathological and analytical variables recognised and recorded in the study. The analysis will be perform in an independent and joint manner in the two cohorts.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Castration Resistant</condition>
  <condition>Cabacitaxel or Docetaxel</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <description>Docetaxel 75mg/m2 iv every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <description>Cabazitaxel 20-25mg/m2 iv every 3 weeks</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Paxgene and tempus tubes on baeline, pre-cycle 3 and progression Tumor paraffine sample at
      baseline
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with Castrationresistant Prostate Cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent.

          2. Eighteen years of age or older.

          3. General health status acceptable and compatible with active treatment: ECOG ≤0-2.

          4. Histological confirmation of prostate cancer diagnosis.

          5. Prior resistance to biochemical castration with an LHRH agonist (or surgical
             castration through bilateral orchiectomy) and progression to an anti-androgen drug
             (e.g. bicalutamide, nilutamide or cyproterone acetate).

          6. Biochemical progression upon prior treatment in agreement with PSAWG2 criteria,
             confirmed by a second PSA test.

          7. Castrate levels of testosterone in peripheral blood: testosterone &lt;0.5 ng/ml.

          8. Candidates for standard treatment with:

               1. docetaxel (75 mg/m2 every three weeks) plus prednisone (5 mg/12 h). or

               2. cabazitaxel (20 or 25 mg/m2 every three weeks) plus prednisone (5 mg/12 h).

          9. Availability of anatomopathological tumour material (e.g. a paraffin block of the
             prostatectomy or initial biopsy of the metastasis).

         10. Acceptable hematological, hepatic and renal functions and without contraindications
             for the administration of docetaxel or cabaziatxel in agreement with its respective
             summary of products characteristics.

        Exclusion Criteria:

          1. Previous cancer diagnosis, except those patients who had a localized malignant tumour
             and who are five years cancer-free, as well as subjects with a history of skin
             cancers (of non-melanoma type) or excised in situ carcinomas.

          2. Medical histories, be they psychiatric or of any other character, which, according to
             the judgement of the investigator, might interfere with the subject's granting of
             informed consent or the safe execution of the procedures required in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Olmos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Prostate Cancer Clinical Research Unit CNIO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuria Romero, MD, PhD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2950</phone_ext>
    <email>nromerol@cnio.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Isabel Pacheco, MD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2951</phone_ext>
    <email>mipacheco@ext.cnio.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urbano Anido, MD</last_name>
      <phone>+34981950000</phone>
      <email>urbanoanido@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep M. Piulats, MD</last_name>
      <phone>+34932607780</phone>
      <email>jmpiulats@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Althaia Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Domenech, MD</last_name>
      <phone>+34938759300</phone>
      <phone_ext>3309</phone_ext>
      <email>mdomenech@althaia.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Viciana, MD</last_name>
      <phone>+34956032075</phone>
      <email>ruthvician@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Villatoro, MD</last_name>
      <phone>+34951976470</phone>
      <email>villatororoldan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Lainez, MD</last_name>
      <phone>+34948255400</phone>
      <phone_ext>5870</phone_ext>
      <email>nuria.lainez.milagro@cfnavarra.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Delia Garcia, MD</last_name>
      <phone>+34922678204</phone>
      <email>rdgmarrero@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Centro Oncologico de Galicia</name>
      <address>
        <city>A Coruna</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Medina, MD</last_name>
      <phone>+34981287499</phone>
      <phone_ext>174</phone_ext>
      <email>ana.medina@cog.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Morales, MD</last_name>
      <phone>+34932746000</phone>
      <phone_ext>4695</phone_ext>
      <email>rafael.morales.barrera@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Carlos Villa, MD</last_name>
      <phone>+34926278000</phone>
      <phone_ext>77137</phone_ext>
      <email>jvillaguzman1@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Mendez, MD</last_name>
      <phone>+34957011147</phone>
      <email>mjosemv@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Luque, MD</last_name>
      <phone>+34958020000</phone>
      <email>rluquecaro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Casinello, MD</last_name>
      <phone>+34949209200</phone>
      <email>jacaes@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Angel Arranz, MD</last_name>
      <phone>+34914269070</phone>
      <email>jarranz@oncomed.gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coordination PROCURE-Centro Nacional de Investigaciones Oncologicas</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Romero, MD</last_name>
      <phone>347328000</phone>
      <phone_ext>2951</phone_ext>
      <email>nromerol@cnio.es</email>
    </contact>
    <contact_backup>
      <last_name>Berta Nasarre, PhD</last_name>
      <email>bnasarre@cnio.es</email>
    </contact_backup>
    <investigator>
      <last_name>Leticia Rivera, CRA senior</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gala Grau, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Isabel Pacheco, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Garces, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Puente, MD</last_name>
      <phone>+34913303000</phone>
      <phone_ext>7332</phone_ext>
      <email>docjavip@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Castellanos, MD</last_name>
      <phone>+34913908339</phone>
      <email>cdanicas@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Francisco Rodriguez Moreno, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Romero, MD</last_name>
      <email>ecastro@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Juan Francisco Rodríguez-Moreno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anatomical Pathology PROCURE</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Isabel Hierro, Prof</last_name>
      <phone>+34951032000</phone>
      <email>misabel.hierro.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Ines de Torres, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Montesa, MD</last_name>
      <phone>+34951291425</phone>
      <email>amontesa@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gonzalez, MD</last_name>
      <phone>+34968360900</phone>
      <phone_ext>3807</phone_ext>
      <email>engonbil@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Isabel Sáez, MD</last_name>
      <email>msaez.med@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aranzazu Gonzalez, MD</last_name>
      <phone>+34871206130</phone>
      <phone_ext>76130</phone_ext>
      <email>aranzazu.gonzalezdealba@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Azpitarte, MD</last_name>
      <phone>+34 986800004</phone>
      <email>crisazpi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lorente, MD</last_name>
      <phone>+34961244000</phone>
      <email>davlorente@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 26, 2017</lastchanged_date>
  <firstreceived_date>February 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
